Display options
Cite
Spaziani M, Tarantino C, Tahani N, et al. Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature. Front Endocrinol (Lausanne). 2021;12:634288doi: 10.3389/fendo.2021.634288.
Spaziani, M., Tarantino, C., Tahani, N., Gianfrilli, D., Sbardella, E., Isidori, A. M., Lenzi, A., & Radicioni, A. F. (2021). Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature. Frontiers in endocrinology, 12634288. https://doi.org/10.3389/fendo.2021.634288
Spaziani, Matteo, et al. "Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature." Frontiers in endocrinology vol. 12 (2021): 634288. doi: https://doi.org/10.3389/fendo.2021.634288
Spaziani M, Tarantino C, Tahani N, Gianfrilli D, Sbardella E, Isidori AM, Lenzi A, Radicioni AF. Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature. Front Endocrinol (Lausanne). 2021 Feb 24;12:634288. doi: 10.3389/fendo.2021.634288. eCollection 2021. PMID: 33716984; PMCID: PMC7943868.
Copy Download .nbib Format: NLM
Share it on

Front Endocrinol (Lausanne). 2021 Feb 24;12:634288. doi: 10.3389/fendo.2021.634288. eCollection 2021.

Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature.

Frontiers in endocrinology

Matteo Spaziani, Chiara Tarantino, Natascia Tahani, Daniele Gianfrilli, Emilia Sbardella, Andrea M Isidori, Andrea Lenzi, Antonio F Radicioni

Affiliations

  1. Section of Medical Pathophysiology and Endocrinology, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
  2. Centre for Rare Diseases, Policlinico Umberto I, Rome, Italy.
  3. Department of Diabetes, Endocrinology and Metabolism, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

PMID: 33716984 PMCID: PMC7943868 DOI: 10.3389/fendo.2021.634288

Abstract

The role of growth hormone (GH) during childhood and adulthood is well established. Once final stature is reached, GH continues to act during the transition, the period between adolescence and adulthood in which most somatic and psychological development is obtained. The achievement of peak bone mass represents the most relevant aspect of GH action during the transition period; however, equally clear is its influence on body composition and metabolic profile and, probably, in the achievement of a complete gonadal and sexual maturation. Despite this, there are still some aspects that often make clinical practice difficult and uncertain, in particular in evaluating a possible persistence of GH deficiency once final stature has been reached. It is also essential to identify which subjects should undergo re-testing and, possibly, replacement therapy, and the definition of unambiguous criteria for therapeutic success. Moreover, even during the transition phase, the relationship between GH substitution therapy and cancer survival is of considerable interest. In view of the above, the aim of this paper is to clarify these relevant issues through a detailed analysis of the literature, with particular attention to the clinical, diagnostic and therapeutic aspects.

Copyright © 2021 Spaziani, Tarantino, Tahani, Gianfrilli, Sbardella, Isidori, Lenzi and Radicioni.

Keywords: body composition; bone; cancer survivors; gonad function; growth hormone deficiency; metabolism; transition period

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Horm Res. 1995;43(5):188-93 - PubMed
  2. Osteoporos Int. 2012 Aug;23(8):2219-26 - PubMed
  3. Growth Horm IGF Res. 2005 Oct;15(5):349-59 - PubMed
  4. J Clin Endocrinol Metab. 2011 Aug;96(8):2330-40 - PubMed
  5. J Endocrinol Invest. 2015 Mar;38(3):377-82 - PubMed
  6. Clin Endocrinol (Oxf). 2004 Feb;60(2):175-84 - PubMed
  7. Metabolism. 1999 Mar;48(3):308-13 - PubMed
  8. Front Endocrinol (Lausanne). 2019 Jul 16;10:450 - PubMed
  9. Front Endocrinol (Lausanne). 2019 Mar 12;10:108 - PubMed
  10. J Clin Endocrinol Metab. 2000 May;85(5):1874-81 - PubMed
  11. J Clin Endocrinol Metab. 2007 Apr;92(4):1442-5 - PubMed
  12. Andrology. 2021 Jan;9(1):168-184 - PubMed
  13. J Clin Endocrinol Metab. 2010 Jun;95(6):2646-54 - PubMed
  14. J Clin Endocrinol Metab. 2011 Jun;96(6):1587-609 - PubMed
  15. J Pediatr. 2004 Nov;145(5):657-61 - PubMed
  16. J Clin Endocrinol Metab. 2005 Jul;90(7):3946-55 - PubMed
  17. J Clin Endocrinol Metab. 2018 Aug 1;103(8):2761-2784 - PubMed
  18. J Clin Endocrinol Metab. 2005 May;90(5):2659-65 - PubMed
  19. J Clin Endocrinol Metab. 2003 Sep;88(9):4124-9 - PubMed
  20. Bone. 2010 Feb;46(2):336-41 - PubMed
  21. J Clin Endocrinol Metab. 2003 Apr;88(4):1658-63 - PubMed
  22. J Endocrinol Invest. 2015 Feb;38(2):171-6 - PubMed
  23. J Pediatr Endocrinol Metab. 2014 Sep;27(9-10):813-20 - PubMed
  24. Circulation. 2001 Jan 30;103(4):520-4 - PubMed
  25. Acta Eur Fertil. 1994 Sep-Oct;25(5):311-7 - PubMed
  26. J Clin Endocrinol Metab. 2005 Jul;90(7):3978-82 - PubMed
  27. J Clin Endocrinol Metab. 2009 Nov;94(11):4195-204 - PubMed
  28. Eur J Endocrinol. 2005 Feb;152(2):165-70 - PubMed
  29. Horm Res. 2009;71(6):364-71 - PubMed
  30. Pituitary. 2009;12(2):125-35 - PubMed
  31. J Clin Endocrinol Metab. 2006 Feb;91(2):432-8 - PubMed
  32. J Clin Endocrinol Metab. 1999 Apr;84(4):1324-8 - PubMed
  33. Clin Endocrinol (Oxf). 2003 Dec;59(6):806-10 - PubMed
  34. Regul Pept. 2009 Nov 27;158(1-3):40-6 - PubMed
  35. Endocr Pract. 2019 Nov;25(11):1191-1232 - PubMed
  36. J Clin Endocrinol Metab. 2005 Aug;90(8):4525-9 - PubMed
  37. J Clin Endocrinol Metab. 2007 Dec;92(12):4664-70 - PubMed
  38. Eur J Endocrinol. 2007 Dec;157(6):695-700 - PubMed
  39. Front Endocrinol (Lausanne). 2019 Jul 31;10:525 - PubMed
  40. J Pediatr Endocrinol Metab. 2003 Mar;16 Suppl 2:327-35 - PubMed
  41. Eur J Endocrinol. 2008 Dec;159 Suppl 1:S53-7 - PubMed
  42. Helv Paediatr Acta Suppl. 1989 Jun;52:1-125 - PubMed
  43. J Clin Endocrinol Metab. 2014 Dec;99(12):4712-9 - PubMed
  44. J Clin Endocrinol Metab. 2001 Mar;86(3):1061-5 - PubMed
  45. J Pediatr Endocrinol Metab. 2000;13 Suppl 6:1327-36 - PubMed
  46. Exp Clin Endocrinol Diabetes. 2010 Oct;118(9):596-601 - PubMed
  47. Eur J Endocrinol. 2012 Jun;166(6):1061-8 - PubMed
  48. J Pediatr Endocrinol Metab. 1997 Jan-Feb;10(1):41-9 - PubMed
  49. Clin Endocrinol (Oxf). 2006 May;64(5):556-60 - PubMed
  50. Pituitary. 2020 Aug;23(4):467-475 - PubMed
  51. Endocr Pract. 2009 Sep-Oct;15 Suppl 2:1-29 - PubMed
  52. J Clin Endocrinol Metab. 2004 Aug;89(8):3890-5 - PubMed
  53. J Clin Endocrinol Metab. 2004 Oct;89(10):4993-8 - PubMed
  54. Psychoneuroendocrinology. 2003 Jul;28(5):612-26 - PubMed
  55. Am Heart J. 2003 Mar;145(3):549-53 - PubMed
  56. J Clin Res Pediatr Endocrinol. 2009;1(5):205-8 - PubMed
  57. Best Pract Res Clin Endocrinol Metab. 2017 Feb;31(1):59-69 - PubMed
  58. J Pediatr Endocrinol Metab. 2012;25(1-2):97-105 - PubMed
  59. J Clin Endocrinol Metab. 2004 Oct;89(10):4857-62 - PubMed
  60. Eur J Endocrinol. 2007 Dec;157(6):701-8 - PubMed
  61. J Clin Endocrinol Metab. 2002 Feb;87(2):477-85 - PubMed
  62. N Engl J Med. 1989 Dec 28;321(26):1797-803 - PubMed
  63. Curr Biol. 2016 May 23;26(10):R432-43 - PubMed
  64. Pituitary. 2020 Aug;23(4):432-456 - PubMed
  65. Minerva Endocrinol. 2012 Dec;37(4):379-89 - PubMed
  66. J Clin Endocrinol Metab. 2000 Dec;85(12):4444-9 - PubMed
  67. Clin Endocrinol (Oxf). 2008 Feb;68(2):247-51 - PubMed
  68. Endocr Dev. 2018;33:46-56 - PubMed
  69. J Endocrinol Invest. 2011 Oct;34(9):709-15 - PubMed
  70. J Pediatr. 1996 May;128(5 Pt 2):S4-7 - PubMed
  71. J Clin Densitom. 2011 Oct-Dec;14(4):471-7 - PubMed
  72. J Clin Endocrinol Metab. 2004 May;89(5):2192-9 - PubMed
  73. J Endocrinol Invest. 2007 Dec;30(11):931-6 - PubMed
  74. Eur J Endocrinol. 2003 Mar;148(3):333-8 - PubMed
  75. J Clin Endocrinol Metab. 2014 Jun;99(6):2030-7 - PubMed
  76. J Clin Endocrinol Metab. 2003 Nov;88(11):5273-80 - PubMed
  77. Growth Horm IGF Res. 2008 Aug;18(4):318-24 - PubMed
  78. Endocr Res. 2019 Feb - May;44(1-2):16-26 - PubMed
  79. J Clin Endocrinol Metab. 2001 Aug;86(8):3494-8 - PubMed
  80. J Clin Endocrinol Metab. 2011 Sep;96(9):2756-61 - PubMed
  81. J Clin Endocrinol Metab. 2002 Jul;87(7):3136-41 - PubMed
  82. Ther Clin Risk Manag. 2018 Nov 23;14:2283-2291 - PubMed
  83. J Clin Endocrinol Metab. 2005 Nov;90(11):6048-54 - PubMed
  84. Eur J Endocrinol. 2013 Mar 15;168(4):565-73 - PubMed
  85. J Clin Endocrinol Metab. 2018 Aug 1;103(8):2794-2801 - PubMed
  86. J Clin Endocrinol Metab. 2007 Apr;92(4):1195-200 - PubMed
  87. J Clin Endocrinol Metab. 1999 Dec;84(12):4516-24 - PubMed
  88. J Pediatr Endocrinol Metab. 2018 Aug 28;31(8):887-894 - PubMed
  89. Int J Environ Res Public Health. 2019 Jan 23;16(3): - PubMed

Publication Types